Biosolution Co.Ltd (KQ:086820) — Market Cap & Net Worth
Market Cap & Net Worth: Biosolution Co.Ltd (086820)
Biosolution Co.Ltd (KQ:086820) has a market capitalization of $110.71 Million (₩163.37 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18881 globally and #890 in its home market, demonstrating a -3.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biosolution Co.Ltd's stock price ₩6770.00 by its total outstanding shares 24130854 (24.13 Million). Review 086820 total debt and obligations to assess the company's total debt and financial obligations.
Biosolution Co.Ltd Market Cap History: 2018 to 2026
Biosolution Co.Ltd's market capitalization history from 2018 to 2026. Data shows change from $533.11 Million to $110.71 Million (-16.77% CAGR).
Index Memberships
Biosolution Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.04% | #358 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.04% | #358 of 1384 |
Weight: Biosolution Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biosolution Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biosolution Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
Biosolution Co.Ltd's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $533.11 Million | $10.53 Billion | $1.35 Billion | 0.05x | 0.40x |
| 2019 | $706.46 Million | $8.88 Billion | -$697.54 Million | 0.08x | N/A |
| 2020 | $481.60 Million | $7.74 Billion | -$1.80 Billion | 0.06x | N/A |
| 2021 | $354.86 Million | $11.80 Billion | -$1.68 Billion | 0.03x | N/A |
| 2022 | $173.34 Million | $10.10 Billion | -$8.09 Billion | 0.02x | N/A |
| 2023 | $317.09 Million | $12.46 Billion | -$1.36 Billion | 0.03x | N/A |
| 2024 | $351.59 Million | $12.89 Billion | -$11.93 Billion | 0.03x | N/A |
Competitor Companies of 086820 by Market Capitalization
Companies near Biosolution Co.Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Biosolution Co.Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Biosolution Co.Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Biosolution Co.Ltd's market cap moved from $533.11 Million to $ 110.71 Million, with a yearly change of -16.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩110.71 Million | -14.41% |
| 2025 | ₩129.35 Million | -63.21% |
| 2024 | ₩351.59 Million | +10.88% |
| 2023 | ₩317.09 Million | +82.92% |
| 2022 | ₩173.34 Million | -51.15% |
| 2021 | ₩354.86 Million | -26.32% |
| 2020 | ₩481.60 Million | -31.83% |
| 2019 | ₩706.46 Million | +32.52% |
| 2018 | ₩533.11 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Biosolution Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $110.71 Million USD |
| MoneyControl | $110.71 Million USD |
| MarketWatch | $110.71 Million USD |
| marketcap.company | $110.71 Million USD |
| Reuters | $110.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more